Bristol-Myers Squibb Co. - BMY Net earnings per share (EPS TTM)

Official company branding of Bristol Myers Squibb (BMY)

Bristol-Myers Squibb (BMY) efficiency relies on R&D and oncology integration to combat the patent cliff. The 12-month net income per share history demonstrates the market reaction, where the 4.48 mark serves as a key metric. Revenue growth is pursued through the acquisition of biotech startups, yet pressure from the loss of exclusivity for Eliquis and Revlimid maintains risks of margin compression.

BMY (Bristol-Myers Squibb) Net earnings per share for the last four quarters history from 07/04/2022 to 11/18/2026

Analytical breakdowns for Bristol-Myers Squibb

- current quotes and average value forecast:
Fundamental company valuation:BMY - Bristol Myers Squibb
Manufactured products of Bristol Myers Squibb Company

Staff optimization and the restructuring of the R&D core at Bristol-Myers Squibb (BMY) directly impact operational efficiency, which is reflected in the trend of net income per share. This trailing 12-month net income per share neutralizes one-time accounting distortions, allowing investors to assess the business's actual ability to generate capital and determine the risk of overpaying when purchasing the asset.